

OssDsign Q1 - An undramatic first quarter

Redeye regards OssDsign's Q1 as a relative non-event quarter; elective surgeries took a major toll in the early months of Q1, but the lower-than-anticipated sales for OssDsign do not render any case reconsiderations, we argue.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[OssDsign Q1 - An undramatic first quarter](#)